FROVA should not be given to patients with ischemic heart disease (e.g. angina pectoris, history of myocardial infarction, or documented silent ischemia), or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal’s variant angina or other significant underlying cardiovascular disease (see WARNINGS).
FROVA should not be given to patients with cerebrovascular syndromes including (but not limited to) strokes of any type as well as transient ischemic attacks.
FROVA should not be given to patients with peripheral vascular disease including (but is not limited to) ischemic bowel disease (see WARNINGS)
FROVA should not be given to patients with uncontrolled hypertension (see WARNINGS).
FROVA should not be administered to patients with hemiplegic or basilar migraine.
FROVA should not be used within 24 hours of treatment with another 5-HT1 agonist, an ergotamine containing or ergot-type medication such as dihydroergotamine (DHE) or methysergide.
FROVA is contraindicated in patients who are hypersensitive to frovatriptan or any of the inactive ingredients in the tablets.